Clinical implications of TP53 mutations (TP53MT) in patients (pts) with higher risk Myelodysplastic Syndromes (HR-MDS) treated with hypomethylating agents (HMA) and allogeneic hematopoietic transplantation (allo-HCT): An analysis from the international consortium of MDS (icMDS) validate databaseTariq Kewan, Angela Consagra, Amy E. DeZern et al.|Blood|2025Cited by 0
The prognostic significance (or lack) of achieving marrow complete remission (mCR) with hypomethylating agent-based therapy in patients with myelodysplastic syndromeBenjamin Rolles, Angela Consagra, Jan Philipp Bewersdorf et al.|Blood|2025Cited by 0
Outcomes of patients (pts) with higher-risk myelodysplastic syndromes (HR-MDS) treated with hypomethylating agents (HMA) + venetoclax (VEN) – a large analysis from the international consortium for MDS (icMDS) validate databaseJan Philipp Bewersdorf, Angela Consagra, Tariq Kewan et al.|Blood|2025Cited by 0